Biostage Company Profile (NASDAQ:BSTG)

About Biostage (NASDAQ:BSTG)

Biostage logoBiostage, Inc., formerly Harvard Apparatus Regenerative Technology, Inc., is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient's own cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, trachea or bronchus that are caused due to cancer, infection, trauma or congenital abnormalities. Its Cellframe technology is engineered to stimulate the body's signaling pathways and natural healing process to regenerate and restore organ function. Its Cellframe technology platform is used to create organ specific Cellspan implants. Its product candidates are in development and have not yet received regulatory approval for sale anywhere in the world.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BSTG
  • CUSIP: N/A
  • Web: www.biostage.com
Capitalization:
  • Market Cap: $19.11 million
  • Outstanding Shares: 37,116,000
Average Prices:
  • 50 Day Moving Avg: $0.39
  • 200 Day Moving Avg: $0.44
  • 52 Week Range: $0.22 - $1.42
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.77
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $82,000.00
  • Price / Sales: 233.11
  • Book Value: $0.04 per share
  • Price / Book: 12.56
Profitability:
  • EBIDTA: ($12,240,000.00)
  • Return on Equity: -338.69%
  • Return on Assets: -180.87%
Debt:
  • Current Ratio: 1.07%
  • Quick Ratio: 1.07%
Misc:
  • Average Volume: 769,476 shs.
  • Beta: 0.13
  • Short Ratio: 3.27
 

Frequently Asked Questions for Biostage (NASDAQ:BSTG)

What is Biostage's stock symbol?

Biostage trades on the NASDAQ under the ticker symbol "BSTG."

How were Biostage's earnings last quarter?

Biostage, Inc. (NASDAQ:BSTG) released its quarterly earnings results on Thursday, May, 11th. The company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.09. View Biostage's Earnings History.

When will Biostage make its next earnings announcement?

Biostage is scheduled to release their next quarterly earnings announcement on Wednesday, August, 9th 2017. View Earnings Estimates for Biostage.

Where is Biostage's stock going? Where will Biostage's stock price be in 2017?

1 brokers have issued 1-year target prices for Biostage's shares. Their predictions range from $3.00 to $3.00. On average, they expect Biostage's stock price to reach $3.00 in the next twelve months. View Analyst Ratings for Biostage.

Who are some of Biostage's key competitors?

Who are Biostage's key executives?

Biostage's management team includes the folowing people:

  • John F. Kennedy, Chairman of the Board
  • Saverio La Francesca M.D., President, Chief Medical Officer
  • James J. McGorry, Chief Executive Officer, Director
  • Thomas McNaughton Jr., Chief Financial Officer
  • Harout DerSimonian, Chief Scientific Officer
  • David M. Green, Director
  • Blaine H Mckee Ph.D., Director
  • John J. Canepa, Independent Director
  • Thomas H. Robinson, Independent Director

How do I buy Biostage stock?

Shares of Biostage can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biostage's stock price today?

One share of Biostage stock can currently be purchased for approximately $0.52.


MarketBeat Community Rating for Biostage (NASDAQ BSTG)
Community Ranking:  3.0 out of 5 (  )
Outperform Votes:  32 (Vote Outperform)
Underperform Votes:  21 (Vote Underperform)
Total Votes:  53
MarketBeat's community ratings are surveys of what our community members think about Biostage and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Biostage (NASDAQ:BSTG) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $3.00 (482.52% upside)

Analysts' Ratings History for Biostage (NASDAQ:BSTG)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/10/2017Maxim GroupReiterated RatingHoldN/AView Rating Details
(Data available from 7/21/2015 forward)

Earnings

Earnings History for Biostage (NASDAQ:BSTG)
Earnings by Quarter for Biostage (NASDAQ:BSTG)
Earnings History by Quarter for Biostage (NASDAQ BSTG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017($0.18)N/AView Earnings Details
5/11/2017Q1 2017($0.23)($0.14)ViewN/AView Earnings Details
3/9/2017Q4 2016($0.21)($0.20)$0.03 millionViewListenView Earnings Details
11/10/2016Q316($0.25)($0.18)$26.00 millionViewN/AView Earnings Details
8/11/2016Q216($0.21)($0.17)$48.00 million$0.03 millionViewListenView Earnings Details
5/12/2016Q1($0.23)($0.18)ViewListenView Earnings Details
3/17/2016Q415($0.17)$1.60 million$0.01 millionViewListenView Earnings Details
11/12/2015Q315($0.19)$37.00 millionViewN/AView Earnings Details
8/13/2015Q215($0.44)$23.00 million$73.00 millionViewN/AView Earnings Details
3/19/2015Q4 2014($0.27)($0.36)$0.05 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.33)($0.34)ViewN/AView Earnings Details
8/8/2014Q214($0.27)($0.32)$0.02 millionViewN/AView Earnings Details
5/8/2014Q114($0.33)($0.39)$0.10 million$0.02 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Biostage (NASDAQ:BSTG)
Current Year EPS Consensus Estimate: $-0.810 EPS
Next Year EPS Consensus Estimate: $-0.670 EPS

Dividends

Dividend History for Biostage (NASDAQ:BSTG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Biostage (NASDAQ:BSTG)
Insider Ownership Percentage: 4.30%
Institutional Ownership Percentage: 6.86%
Insider Trades by Quarter for Biostage (NASDAQ:BSTG)
Insider Trades by Quarter for Biostage (NASDAQ:BSTG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/12/2016Harout DersimonianInsiderBuy10,000$0.91$9,100.00View SEC Filing  
8/26/2016John F KennedyDirectorBuy16,182$0.93$15,049.26View SEC Filing  
8/25/2016James Joseph McgorryInsiderBuy25,000$0.96$24,000.00View SEC Filing  
6/21/2016James Joseph McgorryCEOBuy20,000$1.07$21,400.00View SEC Filing  
6/13/2016Thomas H RobinsonDirectorBuy32,000$1.17$37,440.00View SEC Filing  
5/25/2016John J CanepaDirectorBuy17,241$1.46$25,171.86View SEC Filing  
5/20/2016James Joseph McgorryCEOBuy10,000$1.56$15,600.00View SEC Filing  
5/20/2016John F KennedyDirectorBuy6,500$1.56$10,140.00View SEC Filing  
5/20/2016Thomas McnaughtonCFOBuy5,000$1.56$7,800.00View SEC Filing  
5/19/2016Thomas H RobinsonDirectorBuy18,000$1.36$24,480.00View SEC Filing  
12/17/2015Saverio LafrancescainsiderSell2,393$1.93$4,618.49View SEC Filing  
12/1/2015John F KennedyDirectorBuy9,000$2.95$26,550.00View SEC Filing  
12/1/2015Saverio LafrancescaInsiderBuy10,000$3.01$30,100.00View SEC Filing  
11/19/2015James Joseph McgorryCEOBuy10,000$1.79$17,900.00View SEC Filing  
11/18/2015Thomas McnaughtonCFOBuy10,000$1.56$15,600.00View SEC Filing  
11/17/2015David GreenDirectorBuy25,000$1.34$33,500.00View SEC Filing  
11/17/2015Thomas McnaughtonCFOBuy15,000$1.32$19,800.00View SEC Filing  
9/18/2015Saverio LafrancescainsiderBuy9,500$1.29$12,255.00View SEC Filing  
8/28/2015Saverio LafrancescaInsiderBuy2,500$0.96$2,400.00View SEC Filing  
8/26/2015Thomas McnaughtonCFOBuy10,000$0.88$8,800.00View SEC Filing  
8/24/2015John F KennedyDirectorBuy12,000$0.83$9,960.00View SEC Filing  
8/21/2015James Joseph McgorryCEOBuy31,300$0.74$23,162.00View SEC Filing  
8/21/2015Thomas McnaughtonCFOBuy100,000$0.66$66,000.00View SEC Filing  
6/4/2015John F KennedyDirectorBuy1,000$2.13$2,130.00View SEC Filing  
6/3/2015John F KennedyDirectorBuy1,000$1.95$1,950.00View SEC Filing  
6/3/2015Thomas McnaughtonCEOBuy16,000$1.85$29,600.00View SEC Filing  
6/2/2015David GreenDirectorBuy26,600$1.81$48,146.00View SEC Filing  
6/2/2015Thomas McnaughtonCEOBuy8,000$1.80$14,400.00View SEC Filing  
6/1/2015John F KennedyDirectorBuy10,000$1.67$16,700.00View SEC Filing  
6/1/2015Thomas McnaughtonCEOBuy3,000$1.74$5,220.00View SEC Filing  
5/29/2015Thomas McnaughtonCEOBuy5,000$1.91$9,550.00View SEC Filing  
2/18/2015David GreenCEOBuy50,000$1.75$87,500.00View SEC Filing  
2/13/2015Thomas McnaughtonCFOBuy14,000$2.67$37,380.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Biostage (NASDAQ:BSTG)
Latest Headlines for Biostage (NASDAQ:BSTG)
Source:
DateHeadline
streetinsider.com logoBiostage (BSTG) Granted Continued Listing on Nasdaq - StreetInsider.com
www.streetinsider.com - July 10 at 8:16 PM
finance.yahoo.com logoBiostage Granted Continued Listing on Nasdaq
finance.yahoo.com - July 10 at 3:15 PM
prnewswire.com logoBiostage Announces Agreement to Conduct $3.1 Million Private Placement at Market - PR Newswire (press release)
www.prnewswire.com - June 28 at 2:22 AM
finance.yahoo.com logoBiostage Announces Agreement to Conduct $3.1 Million Private Placement at Market
finance.yahoo.com - June 27 at 4:18 PM
streetinsider.com logoBiostage (BSTG) Says Positive Preclinical Data of Cellspan Esophageal Implant Presented at ISSCR
www.streetinsider.com - June 21 at 1:33 AM
finance.yahoo.com logoBiostage Announces Positive Preclinical Data of Cellspan™ Esophageal Implant Presented at the International Society for Stem Cell Research 2017 Annual Meeting
finance.yahoo.com - June 19 at 12:49 PM
finance.yahoo.com logoBiostage to Present at the 2017 Marcum MicroCap Conference
finance.yahoo.com - June 14 at 4:42 PM
finance.yahoo.com logoBiostage to Present at the Cell and Gene Exchange 2017
finance.yahoo.com - May 23 at 1:01 PM
streetinsider.com logoBiostage (BSTG) Receives Nasdaq Listing Determination; Plans to Request Hearing - StreetInsider.com
www.streetinsider.com - May 22 at 4:00 PM
finance.yahoo.com logoHolliston biotech faces possible delisting, but CEO remains confident
finance.yahoo.com - May 22 at 3:59 PM
finance.yahoo.com logoBiostage Announces Receipt of Nasdaq Listing Determination
finance.yahoo.com - May 22 at 12:51 PM
americanbankingnews.com logoBiostage Inc (BSTG) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 12 at 12:56 PM
seekingalpha.com logoBiostage, Inc. 2017 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 11 at 9:39 PM
seekingalpha.com logoBiostage reports Q1 results
seekingalpha.com - May 11 at 4:38 PM
finance.yahoo.com logoBiostage Reports 2017 First Quarter Financial Results and Provides Business Update
finance.yahoo.com - May 11 at 9:13 AM
finance.yahoo.com logoInvestor Network: Biostage, Inc. to Host Earnings Call
finance.yahoo.com - May 11 at 9:13 AM
finance.yahoo.com logoDr. Christine Finck of Connecticut Children's Medical Center, Presents Data in Poster Presentation from Collaboration with Biostage at the American Pediatric Surgical Association (APSA) 2017 Annual Meeting
finance.yahoo.com - May 9 at 8:38 AM
prnewswire.com logoBiostage to Host 2017 First Quarter Update Conference Call - PR Newswire (press release)
www.prnewswire.com - May 5 at 4:06 PM
finance.yahoo.com logoBiostage to Host 2017 First Quarter Update Conference Call
finance.yahoo.com - May 5 at 4:06 PM
finance.yahoo.com logoBiostage to Present at the American Association for Thoracic Surgery Centennial Meeting
finance.yahoo.com - May 1 at 9:01 AM
americanbankingnews.com logoShort Interest in Biostage Inc (BSTG) Expands By 30.9%
www.americanbankingnews.com - April 29 at 1:15 AM
finance.yahoo.com logoETFs with exposure to Biostage, Inc. : April 28, 2017
finance.yahoo.com - April 28 at 5:02 PM
prnewswire.com logoBiostage to Participate at the Alliance for Regenerative Medicine's 5th Annual Cell & Gene Therapy Investor Day - PR Newswire (press release)
www.prnewswire.com - April 26 at 2:32 PM
finance.yahoo.com logoBiostage to Participate at the Alliance for Regenerative Medicine's 5th Annual Cell & Gene Therapy Investor Day
finance.yahoo.com - April 26 at 2:32 PM
bizjournals.com logoBiotech Stocks Under Scanner -- Biostage, Keryx Biopharma, Kite Pharma, and ZIOPHARM Oncology
www.bizjournals.com - April 20 at 10:49 AM
finance.yahoo.com logoBiostage Appoints Stephen F. Badylak DVM, PhD, MD, as Co-Chairman of Scientific Advisory Board
finance.yahoo.com - April 18 at 12:38 PM
finance.yahoo.com logoETFs with exposure to Biostage, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 9:03 PM
streetinsider.com logoBiostage (BSTG) Highlights Positive Preclincal Data of Cellspan Esophageal Implant at Society For Biomaterials 2017 Conference
www.streetinsider.com - April 7 at 4:02 PM
streetinsider.com logoBiostage (BSTG) Highlights Positive Preclincal Data of Cellspan Esophageal Implant at Society For Biomaterials 2017 ... - StreetInsider.com
www.streetinsider.com - April 7 at 8:41 AM
finance.yahoo.com logoBiostage Presents Positive Preclincal Data of Cellspan Esophageal Implant at Society For Biomaterials 2017 Annual Meeting and Exposition
finance.yahoo.com - April 7 at 8:41 AM
finance.yahoo.com logoBiostage to Participate at the MassBio 2017 Annual Meeting
finance.yahoo.com - March 28 at 1:00 PM
americanbankingnews.com logoBiostage Inc (BSTG) Short Interest Update
www.americanbankingnews.com - March 28 at 8:08 AM
finance.yahoo.com logoBIOSTAGE, INC. Financials
finance.yahoo.com - March 23 at 4:29 PM
biz.yahoo.com logoBIOSTAGE, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 17 at 4:38 PM
prnewswire.com logoBiostage Promotes Saverio La Francesca, MD to President - PR Newswire (press release)
www.prnewswire.com - March 16 at 4:19 PM
finance.yahoo.com logoBiostage Promotes Saverio La Francesca, M.D. to President
finance.yahoo.com - March 16 at 4:19 PM
finance.yahoo.com logo7:12 am Biostage promotes its Chief Medical Officer, Saverio La Francesca, M.D. to additional role as President
finance.yahoo.com - March 16 at 4:19 PM
biz.yahoo.com logoBIOSTAGE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and
biz.yahoo.com - March 16 at 4:19 PM
biz.yahoo.com logoBIOSTAGE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - March 10 at 4:57 PM
biz.yahoo.com logoQ4 2016 Biostage Inc Earnings Release - Before Market Open
biz.yahoo.com - March 9 at 4:36 PM
finance.yahoo.com logoBiostage Reports 2016 Financial Results and Provides Business Update
finance.yahoo.com - March 9 at 4:36 PM
finance.yahoo.com logoBiostage to Host Fiscal Year 2016 Update Conference Call
finance.yahoo.com - March 2 at 4:14 PM
finance.yahoo.com logoBiostage Announces Closing of $8.0 Million Public Offering
finance.yahoo.com - February 17 at 11:07 AM
247wallst.com logoBiostage, Fossil Group Tumble into Friday's 52-Week Low Club - 24/7 Wall St.
247wallst.com - February 11 at 1:37 AM
streetinsider.com logoBiostage (BSTG) Prices Offering at $0.40/Share, With Warrants to Boot - StreetInsider.com
www.streetinsider.com - February 11 at 1:37 AM
finance.yahoo.com logoBiostage, Fossil Group Tumble into Friday's 52-Week Low Club - Yahoo Finance
finance.yahoo.com - February 10 at 8:36 PM
finance.yahoo.com logoBiostage Announces $8.0 Million Public Offering
finance.yahoo.com - February 10 at 3:35 PM

Social

Chart

Biostage (BSTG) Chart for Friday, July, 21, 2017

This page was last updated on 7/21/2017 by MarketBeat.com Staff